Literature DB >> 6329999

Plasmapheresis combined with lymphocytapheresis and cytotoxic drugs as a therapeutic modality in neuroimmunological diseases.

M Valbonesi, F Montani, G Florio, D Zerbi, A Beltramelli.   

Abstract

Rebound after plasmapheresis is thought to be due to enhanced antibody and/or immune complex production. To prevent rebound a combination of steroids and immunosuppressive drugs has been used: lymphocytapheresis was employed in most patients, for not more than 10 sessions. 50 patients with myasthenia gravis, inflammatory myopathy, chronic dysimmune polyneuropathy and immune complex polyneuropathy have been treated and long-lasting benefits obtained in 35 patients. Rebound effects were observed only when cytotoxic drugs were not given or discontinued too soon. 8 patients who had been treated by plasmapheresis combined with steroids alone, after some recurrences of their disease, were switched to cytotoxic drugs, steroids and lymphocytapheresis combined with plasma exchange: in this group 7 patients eventually gained long lasting remissions. Our clinical experience strongly supports the hypothesis of a synergy between plasmapheresis and immuno-suppressive measures.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329999     DOI: 10.1007/bf02043967

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  11 in total

1.  Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone.

Authors:  R D Rossen; E M Hersh; J T Sharp; K B McCredie; F Gyorkey; W N Suki; G Eknoyan; M A Reisberg
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

2.  Management of immune-mediated and paraproteinemic diseases by membrane plasma separation and cascade filtration.

Authors:  M Valbonesi; S Garelli; F Montani; M Cefis; U Rossi
Journal:  Vox Sang       Date:  1982       Impact factor: 2.144

3.  Experience with plasmapheresis in 153 neurologic patients.

Authors:  P C Dau; R G Miller; E H Denys
Journal:  Int J Artif Organs       Date:  1982-01       Impact factor: 1.595

4.  The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange.

Authors:  M L Gross; P K Thomas
Journal:  J Neurol Sci       Date:  1981-10       Impact factor: 3.181

5.  Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia.

Authors:  E M Berkman; J B Orlin
Journal:  Transfusion       Date:  1980 Mar-Apr       Impact factor: 3.157

6.  Plasma exchange in rheumatoid vasculitis.

Authors:  D G Scott; P A Bacon; J E Bothamley; C Allen; C J Elson; T B Wallington
Journal:  J Rheumatol       Date:  1981 May-Jun       Impact factor: 4.666

7.  Plasma exchange in the treatment of immune disease.

Authors:  R F Branda; C F Moldow; J J McCullough; H S Jacob
Journal:  Transfusion       Date:  1975 Nov-Dec       Impact factor: 3.157

8.  Plasma exchange in management of a patient with diffuse necrotizing cutaneous vasculitis.

Authors:  M Valbonesi; S Garelli; L Mosconi; G Camerone; G Bedarida; G Di Guardo
Journal:  Vox Sang       Date:  1980-11       Impact factor: 2.144

9.  Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.

Authors:  M C Dalakas; W K Engel
Journal:  Ann Neurol       Date:  1981       Impact factor: 10.422

10.  Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion.

Authors:  J C Bystryn; M W Graf; J W Uhr
Journal:  J Exp Med       Date:  1970-12-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators.

Authors:  Hussam Baghdadi; Nada Abdel-Aziz; Nagwa Sayed Ahmed; Hany Salah Mahmoud; Ayman Barghash; Abdullah Nasrat; Manal Mohamed Helmy Nabo; Salah Mohamed El Sayed
Journal:  Int J Health Sci (Qassim)       Date:  2015-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.